Eli Lilly and Company Financial Statements (LLY)
|
|
|
|
Report date
|
|
|
19.02.2020 |
17.02.2021 |
23.02.2022 |
22.02.2023 |
21.02.2024 |
|
30.10.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
22 320 |
24 540 |
28 318 |
28 541 |
34 124 |
|
40 863 |
|
Operating Income, bln rub |
|
|
4 974 |
6 058 |
6 357 |
7 127 |
10 325 |
|
14 436 |
|
EBITDA, bln rub |
? |
|
6 899 |
8 913 |
8 043 |
8 661 |
8 568 |
|
12 514 |
|
Net profit, bln rub |
? |
|
4 638 |
6 194 |
5 582 |
6 245 |
5 240 |
|
8 370 |
|
|
OCF, bln rub |
? |
|
4 837 |
6 500 |
7 261 |
7 084 |
4 240 |
|
6 032 |
|
CAPEX, bln rub |
? |
|
1 354 |
2 029 |
1 873 |
2 484 |
7 392 |
|
8 211 |
|
FCF, bln rub |
? |
|
3 483 |
4 471 |
5 388 |
4 600 |
-3 152 |
|
-2 179 |
|
Dividend payout, bln rub
|
|
|
2 410 |
2 687 |
3 087 |
3 536 |
4 069 |
|
4 530 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
52.0% |
43.4% |
55.3% |
56.6% |
77.7% |
|
54.1% |
|
|
OPEX, bln rub |
|
|
11 809 |
12 207 |
13 458 |
13 631 |
16 717 |
|
18 893 |
|
Cost of production, bln rub |
|
|
4 721 |
5 483 |
7 313 |
6 630 |
7 082 |
|
7 534 |
|
R&D, bln rub |
|
|
5 595 |
6 086 |
7 026 |
7 191 |
9 313 |
|
10 531 |
|
Interest expenses, bln rub |
|
|
400.6 |
359.6 |
339.8 |
331.6 |
485.9 |
|
603.8 |
|
|
Assets, bln rub |
|
|
39 286 |
46 633 |
48 806 |
49 490 |
64 006 |
|
75 607 |
|
Net Assets, bln rub |
? |
|
2 607 |
5 642 |
8 979 |
10 650 |
10 772 |
|
14 240 |
|
Debt, bln rub |
|
|
15 804 |
16 595 |
16 885 |
16 239 |
25 225 |
|
31 120 |
|
Cash, bln rub |
|
|
2 439 |
3 681 |
3 909 |
2 212 |
2 928 |
|
3 518 |
|
Net debt, bln rub |
|
|
13 365 |
12 914 |
12 976 |
14 027 |
22 298 |
|
27 601 |
|
|
Ordinary share price, rub |
|
|
131.4 |
168.8 |
276.2 |
365.8 |
582.9 |
|
579.6 |
|
Number of ordinary shares, mln |
|
|
931.1 |
907.6 |
907.0 |
901.7 |
900.2 |
|
901.0 |
|
|
Market cap, bln rub |
|
|
122 369 |
153 245 |
250 521 |
329 891 |
524 734 |
|
522 220 |
|
EV, bln rub |
? |
|
135 734 |
166 159 |
263 497 |
343 918 |
547 031 |
|
549 821 |
|
Book value, bln rub |
|
|
-7 691 |
-5 575 |
-2 605 |
-630 |
-1 074 |
|
1 934 |
|
|
EPS, rub |
? |
|
4.98 |
6.82 |
6.15 |
6.93 |
5.82 |
|
9.29 |
|
FCF/share, rub |
|
|
3.74 |
4.93 |
5.94 |
5.10 |
-3.50 |
|
-2.42 |
|
BV/share, rub |
|
|
-8.26 |
-6.14 |
-2.87 |
-0.70 |
-1.19 |
|
2.15 |
|
|
EBITDA margin, % |
? |
|
30.9% |
36.3% |
28.4% |
30.3% |
25.1% |
|
30.6% |
|
Net margin, % |
? |
|
20.8% |
25.2% |
19.7% |
21.9% |
15.4% |
|
20.5% |
|
FCF yield, % |
? |
|
2.85% |
2.92% |
2.15% |
1.39% |
-0.60% |
|
-0.42% |
|
ROE, % |
? |
|
177.9% |
109.8% |
62.2% |
58.6% |
48.6% |
|
58.8% |
|
ROA, % |
? |
|
11.8% |
13.3% |
11.4% |
12.6% |
8.19% |
|
11.1% |
|
|
P/E |
? |
|
26.4 |
24.7 |
44.9 |
52.8 |
100.1 |
|
62.4 |
|
P/FCF |
|
|
35.1 |
34.3 |
46.5 |
71.7 |
-166.5 |
|
-239.7 |
|
P/S |
? |
|
5.48 |
6.24 |
8.85 |
11.6 |
15.4 |
|
12.8 |
|
P/BV |
? |
|
-15.9 |
-27.5 |
-96.2 |
-523.8 |
-488.4 |
|
270.0 |
|
EV/EBITDA |
? |
|
19.7 |
18.6 |
32.8 |
39.7 |
63.8 |
|
43.9 |
|
Debt/EBITDA |
|
|
1.94 |
1.45 |
1.61 |
1.62 |
2.60 |
|
2.21 |
|
|
R&D/CAPEX, % |
|
|
413.4% |
299.9% |
375.1% |
289.5% |
126.0% |
|
128.3% |
|
|
CAPEX/Revenue, % |
|
|
6.06% |
8.27% |
6.61% |
8.70% |
21.7% |
|
20.1% |
|
| Eli Lilly and Company shareholders |
